Artrya Ltd
ASX:AYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Artrya Ltd
Change in Working Capital
Artrya Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Artrya Ltd
ASX:AYA
|
Change in Working Capital
AU$4.1m
|
CAGR 3-Years
62%
|
CAGR 5-Years
184%
|
CAGR 10-Years
N/A
|
|
|
4DMedical Ltd
ASX:4DX
|
Change in Working Capital
-AU$1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Change in Working Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pro Medicus Ltd
ASX:PME
|
Change in Working Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alcidion Group Ltd
ASX:ALC
|
Change in Working Capital
AU$148k
|
CAGR 3-Years
40%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
|
B
|
BlinkLab Ltd
ASX:BB1
|
Change in Working Capital
AU$375.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Artrya Ltd
Glance View
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). The company is headquartered in Perth, Western Australia. The company went IPO on 2021-11-26. The firm is focused on operating diagnostic imaging center. The company is primarily engaged in providing powered image-analysis software for coronary artery disease. Its non-invasive solution, Salix uses artificial intelligence (AI) to produce a 3D image and report that provides an accurate detection of coronary artery disease, including the presence of vulnerable plaque. Salix offers precision medicine for cardiac care. The company enables clinicians to triage patients and identify individuals at high risk of heart attack. The firm's cardiac-health report provides diagnostic support to radiologists and cardiologists.
See Also
What is Artrya Ltd's Change in Working Capital?
Change in Working Capital
4.1m
AUD
Based on the financial report for Jun 30, 2025, Artrya Ltd's Change in Working Capital amounts to 4.1m AUD.
What is Artrya Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
184%
Over the last year, the Change in Working Capital growth was 450%. The average annual Change in Working Capital growth rates for Artrya Ltd have been 62% over the past three years , 184% over the past five years .
